Actuate Therapeutics ($ACTU) is a clinical-stage biopharma developing elraglusib, a GSK-3 inhibitor for cancer and inflammatory diseases, with a lead program in randomized Phase 2 for metastatic pancr

The company raised $22.4 million, offering 2.8 million shares — 150,000 fewer than anticipated. Titan Partners Group served as sole bookrunner, with Newbridge Securities Corporation also on the deal. The lead candidate, elraglusib, is licensed from University of Illinois-Chicago and Northwestern. Top-line data from the Phase 2 pancreatic cancer trial is expected in Q1 2025 — a near-term catalyst that will define the story. The downsized raise and low-end pricing signal weak demand amid a selective biotech IPO window. Investors are showing caution toward early-stage oncology names dependent on near-term clinical readouts. Bottom line: $ACTU is a binary bet on a Q1 2025 readout. The small raise limits runway, and the pricing tells you institutions wanted a discount. Watch the data — that's the whole thesis.

The company raised $22.4 million, offering 2.8 million shares — 150,000 fewer than anticipated. Titan Partners Group served as sole bookrunner, with Newbridge Securities Corporation also on the deal.